Incendia Therapeutics

Incendia Therapeutics is a clinical-stage biotechnology company discovering and developing novel monoclonal antibody therapies that disrupt the tumor microenvironment (TME) to improve cancer outcomes. The Company’s science is targeting immune-excluded tumors, an identifiable, prevalent solid tumor phenotype. Incendia’s unique approach breaks down physical and biochemical barriers within the TME to enhance host immune cell infiltration into tumors and enable cancer therapeutics to reach their targets across a broad range of solid cancers. Incendia believes that there are multiple novel opportunities within the TME to target treatment of cancer and improve outcomes. Incendia’s most advanced investigational therapeutic is PRTH-101, a novel therapeutic antibody that binds to and inhibits Discoidin Domain Receptor 1 (DDR1), an element of the TME that is highly expressed by cancer cells in multiple solid tumor types. The Company is currently recruiting patients into a Phase 1c clinical trial with PRTH-101 for the treatment of patients with advanced solid tumors (thymic carcinoma).